



Methylglyoxal  is  a  highly  reactive α-
oxoaldehyde  that  is  formed  in  cells 
primarily  from  the  triose  phosphate 
intermediates  of  glycolysis,  dihy-
droxyacetone phosphate and glycer-
aldehyde  3-phosphate.  In  diabetes, 
hyperglycemia  triggers  enhanced 
production  of  methylglyoxal,  one
consequence  of  which  is  the  rapid 
modification  of  proteins  and  other 
substrates  to  generate  what  are 
called  advanced  glycation  end 
products,  or  AGEs  (Figure  1;  Shi-
nohara et  al.,  1998).  In  this  issue of 
Cell,  Brownlee  and  colleagues  (Yao 
et  al.,  2006)  propose  a  mechanism 
by which methylglyoxal modification 
of  the  corepressor  protein  mSin3A 




expression  and  could  contribute  to 
complications in diabetic patients.
Yao  et  al.  (2006)  studied  Müller 
glia  cells  of  the  rat  retina  and  show 
that  glycolytic  flux  driven  by  high 
concentrations of glucose resulted in 
increased methylglyoxal modification 
of  the  corepressor  protein  mSin3A. 
The  principal  targets  of  methylgly-
oxal  modification  are  arginine  resi-
dues, yielding end products such as 
argpyrimidine and hydroimidazolone. 
Exquisite  studies  performed  by  Yao 
et  al.  (2006)  identified  the  culprit 




aminyltransferase  (OGT)  to  a  com-




critical  events  diminished  the  bind-
ing  of  the  repressor  complex  to  a 
glucose-responsive  GC  box  in  the 
angiopoietin-2  promoter,  thereby 
increasing  expression  of  the  angio-
poietin-2  gene.  Molecules  such  as 
angiopoietin-2  and  other  proangio-
genic factors are key contributors to 
proliferative changes  that character-
ize  the  advanced  stages  of  diabetic 










of  diabetes  and  in  other  contexts, 
such  as  cancer,  renal  failure,  aging, 
infection, and inflammation.
It is well established that AGEs may 
exert  multiple  and  diverse  effects 
in  diabetes  and  other  pathological 
conditions.  AGEs  may  result  in  the 
crosslinking  of  structural  and  base-
ment membranes, thereby modifying 
key  cellular  structures  that  impact 
permeability  and  cellular  motility.  In 




upregulate  production  of  a  host  of 
inflammatory  molecules  and  mol-
ecules provoking tissue injury, which 
contributes  to  the  development  of 
accelerated  atherosclerosis  and 
microvascular  complications  in  dia-
betes  such  as  nephropathy  (Rama-
samy et al., 2005).
AGEs  also  may  modulate  inter-
actions  between  cells.  AGEs  have 
been  found  on  lymphocytes,  rais-
ing  the  question  of  whether  these 
modifications  are  biomarkers  of  the 
aging  or  diabetic  state  or  whether 
they  alter  antigen  presentation  and 
T  cell  responses  (Poggioli  et  al., 
2002).  Recent  studies  suggest  that 
glycation may promote dendritic cell 
development  but  impair  the  ability 
of  these cells  to stimulate primary T 
cell responses (Price et al., 2004). It 
is  plausible  that modulation  of  cog-
nate  dendritic  cell-T  cell  responses 
by  AGE  modifications  may  redirect 
immune  responses  in AGE-enriched 
environments.  Based  on  the  evi-
dence that AGEs derived from meth-
ylglyoxal  or  other  sources  trigger 
maladaptive  responses  in  multiple 
tissues  in  diabetes  or  aging,  block-
ers  of  AGE  production  and  stimula-
tors  of  AGE  degradation  have  been 
developed  and  are  being  tested  in 
clinical trials.
The  enzyme  glyoxalase  I  is  a 
critical  defense  against  glycation  in 
vivo  (Thornalley  1993).  Glyoxalase  I 
detoxifies  reactive  α-oxoaldehydes, 
thereby  removing  deleterious  spe-
cies such as methylglyoxal. However, 
depletion of glutathione, as observed 
in  settings  of  oxidative  stress,  sup-
presses activity of glyoxalase  I. One 
consequence  of  oxidative  stress  is 
decreased  glutathione,  which  could 
lead  to  enhanced  accumulation  of 
methylglyoxal  and  methylglyoxal-
derived AGEs via decreased activity 
of  glyoxalase  I.  Also,  evidence  sug-
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gests that the generation of reactive 
oxygen  species  is  increased  in  dia-
betes  (Nishikawa  et  al.,  2000)  and 
that AGEs themselves may generate 
reactive  oxygen  species.  The  inter-
action  of  AGEs  with  RAGE  results 
in  oxidative  stress  via  activation  of 
NADPH  oxidase  and  mitochondrial 
pathways  (Ramasamy  et  al.,  2005). 
Also,  the modification of  antioxidant 
proteins by methylglyoxal may dimin-
ish  their  function,  thereby  further 
magnifying  the  generation  of  reac-
tive  oxygen  species.  Thus,  unless 
the  cycle  is  broken,  conditions 
favoring  oxidative  stress  may  syn-
ergize  with  hyperglycemia,  uremia 
(the  retention  of  waste  products  in 
the  blood  due  to  renal  failure),  and 
aging  to  propel  sustained  methylg-
lyoxal  generation.  In  the  studies  by 
Brownlee and colleagues (Yao et al., 
2006),  the  authors  provide  critical 
evidence linking oxidative stress and 
methylglyoxal-induced  modification 
of  mSin3A.  Specifically,  in  addition 
to  overexpression  of  glyoxalase  I  in 
retinal  Müller  cells,  overexpression 




The  studies  of Brownlee  and  col-
leagues (Yao et al., 2006) also high-
light  exciting  possibilities  for  cancer 
research. Certainly the role of angio-
poeitin-2  extends  beyond  Müller 
cells  and  pathological  angiogenesis 
in  the  glucose-laden  retina,  consid-
ering  the  critical  biological  impor-
tance of angiogenesis in cancer. The 
next step is to examine whether and 
how  methylglyoxal  modification  of
transcription  factors  contributes  to 
oncogenesis  (perhaps  by  regulat-
ing  genes  involved  in  metastasis  or 
angiogenesis).  In addition  to protein 
substrates,  methylglyoxal  may  gly-
cate  DNA  (Thornalley,  2003).  The 
presence of nucleotide AGEs in DNA 
may  be  associated  with  increased 
frequency of mutations, DNA strand 
breaks,  and  cytotoxicity.  In  the  ure-
mic  environment,  DNA  glycation 
may increase the incidence of malig-
nancy.  In  the  tumor milieu,  the con-
sequences of  glycation  triggered by 
methylglyoxal  modification  of  DNA 
may be exacerbated by concomitant 










could  also  promote  the  apoptosis 
of tumor cells. S-p-bromobenzylglu-
tathione  diesters  have  been  devel-
oped that inhibit glyoxalase I activity. 
These  compounds  facilitate  accu-
mulation of methylglyoxal and induce 




activity.  Thus,  at  multiple  stages  in 
tumorigenesis  and  tumor  progres-
sion,  methylglyoxal-triggered  glyca-
tion may  leave  its mark. Although  in 
certain biological contexts, suppres-
sion  of  methylglyoxal  and  methylg-
lyoxal-modified  species may help  to
prevent or treat disease, in other set-
tings,  harnessing  the  potent  power 
of methylglyoxal may fill a critical void 
in  tumor  therapy,  the  development 
of  agents  that  stimulate  tumor  cell 
apoptosis.
Taken  together,  the  findings  of 
Brownlee and colleagues add to the 




highlights  that,  in  addition  to  direct 
glycation  of  nucleotides  with  its 





have  identified  a  new  link  between 
glycation  of  protein  residues  and
the  modulation  of  gene  expression. 
These findings highlight the power of 









figure 1. Methylglyoxal: Changing the face of the Proteome and the Genome
Many  factors contribute  to  the accumulation of methylglyoxal,  including hyperglycemia, uremia, 
oxidative stress, aging, and inflammation. Methylglyoxal can react with and modify both proteins 
and DNA, leading to the generation of advanced glycation end products (AGEs). The modification 
of  targets  by methylglyoxal  and  its  derivatives  contributes  to  upregulation  of  inflammatory  and 
tissue-injury-provoking molecules (at least in part through the interaction of AGEs with their recep-
tor RAGE), gene transcription, protein crosslinking, and apoptosis. In this issue of Cell, Brownlee 
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Double-strand  breaks  (DSBs)  are  a 
dangerous  form  of  DNA  damage. 
Unrepaired or misrepaired DNA ends 
can  cause  detrimental  outcomes  for 
cells  and  organisms,  including  cell 
death,  chromosomal  instability,  and 
neoplastic  transformation  (Mills  et  al., 
2003). These catastrophic lesions are 
generated  during  normal  metabolic 
processes such as DNA replication or 
upon  exposure  to  exogenous  agents 
such  as  ionizing  radiation  or  cer-
tain  chemotherapeutic  compounds. 
Several  pathways  exist  that  recog-
nize  and  repair  these  lesions,  includ-
ing  the  nonhomologous  end-joining 
(NHEJ) pathway, which serves to pro-
tect  and  directly  ligate  broken  ends 
(Haber,  2000).  Remarkably,  despite 
the inherent risks, there are examples 
throughout  nature  where  organisms 
have  evolved  systems  to  intentionally 
induce  DSBs.  These  processes  usu-
ally  function  to  increase  diversity  of 
species  or  somatic  cells  by  initiating 
the rearrangement of DNA at specific 
regions of  the genome. An  incredible 
example  of  this  is  V(D)J  recombina-
tion,  which  occurs  during  B  and  T 
lymphocyte  development  to  generate 
the  vast  diversity  of  antigen  recep-
tor  genes  that  form  the  basis  of  the 
adaptive  arm  of  our  immune  system. 
Although  this  process  is  initiated  by 
lymphoid-specific  factors,  the  rear-




discovered:  Ku70,  Ku80,  the  DNA-
dependent  protein  kinase  catalytic 
subunit (DNA-PKcs), Artemis, XRCC4 
and  DNA  Ligase  IV.  Ku70  and  Ku80 
comprise a heterodimer  that binds  to 
DNA ends  and  recruits DNA-PKcs,  a 
serine/threonine protein kinase. DNA-
PKcs forms a functional complex with 






tures  containing  single-  to  double-




is  provided  by  Ligase  IV  in  complex 
with  the  XRCC4  cofactor.  Together, 
these  six  proteins  possess  the major 
activities  required  for  NHEJ,  which 




DnA Double-strand Break Repair:  
A Relentless Hunt Uncovers new Prey








A major pathway for repair of DNA double-strand breaks is nonhomologous end-joining 
(NHEJ). In this issue of Cell, Buck et al. (2006a) and Ahnesorg et al. (2006) report the discovery 
of a new NHEJ factor called Cernunnos-XLF. Both groups report that this protein is mutated 
in a rare inherited human syndrome characterized by severe immunodeficiency, develop-
mental delay, and hypersensitivity to agents that cause DNA double-strand breaks.
